Epithelioid Sarcoma Responds to the Oral EZH2 Inhibitor Tazemetostat

Article navigation

Research Watch| December 01 2020

Online ISSN: 2159-8290

Print ISSN: 2159-8274

2020

American Association for Cancer Research.

Cancer Discov (2020) 10 (12): OF12.

Abstract

Tazemetostat produced an overall response rate of 15% and median overall survival of 19.0 months.

2020

American Association for Cancer Research.

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.